Ketanest-S Multi-Dose (Esketamine)

Esketamine blocks the NMDA receptor’s phencyclidine site, preventing excitatory neurotransmission in the brain. This inhibition reduces neuronal firing, leading to dissociative anesthesia, analgesia, and amnesia while preserving respiratory drive at typical clinical doses.

The dose of Ketanest‑S Multi‑Dose is determined by the prescribing clinician based on the patient’s age, weight, medical condition, and the specific procedure. The product is supplied as a multi‑dose vial for preparation and administration by qualified healthcare professionals.

Safety data for esketamine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with traditional agents such as propofol or thiopental, esketamine provides rapid onset of dissociative anesthesia with less respiratory depression, but it may cause higher blood‑pressure spikes and emergence phenomena. Choice of agent depends on the clinical scenario, patient comorbidities and provider preference.

Ketanest‑S Multi‑Dose should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. Once removed from refrigeration, it may be kept at controlled room temperature for a limited period as indicated in the product labeling.

The injectable solution is administered intravenously or intramuscularly by a qualified clinician. The dose is drawn from the multi‑dose vial, diluted if required, and given as a rapid bolus or infusion, with continuous monitoring of vital signs throughout the procedure.

Serious risks include severe hypertension, respiratory depression requiring airway support, emergence reactions such as agitation or hallucinations, laryngospasm, and rare seizures. Prompt recognition and appropriate supportive measures are essential to mitigate these complications.

Patients with uncontrolled hypertension, known hypersensitivity to esketamine or other NMDA antagonists, severe psychiatric disorders (e.g., uncontrolled schizophrenia), or those taking contraindicated medications such as MAO inhibitors should not receive Ketanest‑S Multi‑Dose unless a risk‑benefit assessment justifies its use.